News | Nuclear Imaging | March 10, 2020

MEDraysintell Releases Unique Cyclotron Directory

The report provides an extensive review of all cyclotrons installed or recently sold in all countries and regions of the world with an exhaustive profile of the 15 companies currently developing and/or supplying cyclotrons, along with a description of twelve firms that were active in this market in the past, but which no longer offer cyclotrons for sale, either as the company was taken over or they have ceased that activity

 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide

March 10, 2020 — MEDraysintell released its new and unique report “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide. This second edition of the Cyclotrons Report and Directory is the result of a comprehensive collection of data over the past year that allowed MEDraysintell to identify as many as 1,484 cyclotrons dedicated to the production of medical radionuclides installed worldwide. This 450-page report provides an extensive review of all cyclotrons installed or recently sold in all countries and regions of the world with an exhaustive profile of the 15 companies currently developing and/or supplying cyclotrons, along with a description of twelve firms that were active in this market in the past, but which no longer offer cyclotrons for sale, either as the company was taken over or they have ceased that activity. The global cyclotron market was valued at more than $180 million in 2019. The top three main suppliers of cyclotrons do share almost 70 percent of the world market installed base (in units), and some new comers entered the market recently.

Related Content

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

News | Radiation Oncology | July 28, 2021
July 28, 2021 — IntraOp Medical Corporation announced that ...
Recommendations address when and how radiation therapy should be used and outline best practices for patient-centered care

Figure 1. The guideline also includes treatment algorithms for initial local management (Figure 1) and local management following an unplanned excision (Figure 2).

News | Radiation Therapy | July 27, 2021
July 27, 2021 — A ...
Radiation oncologists urged Congress to reverse proposed CMS cuts and create more equity in access to cancer treatments

Getty Images

News | Radiation Oncology | July 26, 2021
July 26, 2021 — A record number of radiation oncologists met with Congressional leaders and staff last week as part o
ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

Getty Images

News | Radiation Therapy | July 20, 2021
July 20, 2021 — In response to consecutive weeks of proposed...

Positrigo founders Max Ahnen, Ph.D. (left) and Jannis Fischer, Ph.D.

News | PET Imaging | July 16, 2021
American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27

Getty Images

News | ASTRO | July 08, 2021
July 8, 2021 — Registration opens today for the American Society for Radiation Oncology's (...
Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia

Getty Images

News | PET Imaging | July 08, 2021
July 8, 2021 — Biogen and...
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

Image courtesy of JNM

News | PET Imaging | June 28, 2021
June 28, 2021 — The U.S.
The two-year project focused on reducing the use of extended-fraction radiation therapy to treat pain from incurable cancer that had spread to patients’ bones. Once a standard practice, the American Society for Radiation Oncology (ASTRO) has recommended against the routine use of extended-fraction radiation to relieve pain from bone metastases, especially more than 10 treatments.

Multiple cancer metastasis to the pelvic bone and femur bones. Getty Images

News | Radiation Therapy | June 24, 2021
June 24, 2021 — An effort by the Michigan Radiation Oncology Quality Consortium ...